Showing 3681-3690 of 5773 results for "".
- Sight Sciences OMNI Surgical System to Be Featured in Multiple Presentations at the 2022 ESCRShttps://modernod.com/news/sight-sciences-omni-surgical-system-to-be-featured-in-multiple-presentations-at-the-2022-escrs/2481099/Sight Sciences announced that its OMNI Surgical System will be featured in seven clinical presentations at the 2022 European Society of Cataract & Refractive Surgeons (ESCRS) meeting in Milan, Italy from September 16-20. At Sight Sciences Booth A2
- Shamir Glacier PLUS Metaform on 1.6 and 1.67 Now Availablehttps://modernod.com/news/shamir-glacier-plus-metaform-on-16-and-167-now-available/2481093/Shamir announced the availability of the new Glacier PLUS Metaform lens-coating technology, which uses fewer resources and chemicals in its production than its premium AR coating, making it an eco-friendly option for consumers. According to Shamir, features of the new len
- Heru Expands Wearable Platform with Launch of Dark Adaptationhttps://modernod.com/news/heru-expands-wearable-platform-with-launch-of-dark-adaptation-establishing-market-leading-amd-portfolio/2481090/Heru announced the launch of dark adaptation, the newest modality added to its wearable health and wellness platform’s vision screening line-up. Dark adaptation measures the eye’s ability to adjust from light to dark environments. Impaired dark adaptation may be one of the
- Johnson & Johnson Vision Launches Acuvue Oasys Max 1-Dayhttps://modernod.com/news/johnson-johnson-vision-launches-acuvue-oasys-max-1-day/2481083/Johnson & Johnson Vision Care announced the launch of its newest innovation, Acuvue Oasys Max 1-Day contact lenses and Acuvue Oasys Max 1-Day Multifocal contact lenses for presbyopia. The lenses are designed with a combination of new technologies to help meet the needs of digit
- Neurolens Raises $67 Million Investment to Develop New Products and Accelerate Adoptionhttps://modernod.com/news/neurolens-raises-67-million-investment-to-develop-new-products-and-accelerate-adoption/2481080/Neurolens announced completion of a $67 million financing to fuel continued product innovation and growth initiatives, further accelerating the adoption of Neurolens. The financing was led by MVM Partners, with additional participation from Falcon Vision/KKR, Marshall Wac
- Cellusion and Celregen Enter into License Agreement of CLS001 for a Corneal Endothelial Cell Regenerative Therapy in the Greater Chinahttps://modernod.com/news/cellusion-and-celregen-enter-into-license-agreement-of-cls001-for-a-corneal-endothelial-cell-regenerative-therapy-in-the-greater-china/2481079/Cellusion, a Japanese regenerative medicine startup, and Hangzhou Celregen Therapeutics, a member of Shanghai Fosun Pharmaceutical, announced an exclusive license agreement in the Greater China region for Celregen to develop, manufacture and commercialize CLS001. Under the agr
- ESCRS Launches New Awards Program to Foster Digital Transformationhttps://modernod.com/news/escrs-launches-new-awards-program-to-foster-digital-transformation/2481078/The European Society of Cataract & Refractive Surgeons (ESCRS) announced the launch of the 2022 ESCRS Digital Research Awards (DRA), an initiative sponsored by the society to support and encourage innovative research that leads to digital transformation in the fields of cataract, re
- Tarsus Submits New Drug Application to the FDA for TP-03 for the Treatment of Demodex Blepharitishttps://modernod.com/news/tarsus-submits-new-drug-application-to-the-fda-for-tp-03-for-the-treatment-of-demodex-blepharitis/2481073/Tarsus Pharmaceuticals announced that it has submitted a new drug application (NDA) to the FDA for TP-03 (lotilaner ophthalmic solution, 0.25%) for the treatment of Demodex blepharitis. Demodex blepharitis is a highly prevalent eyelid m
- Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and Wet AMD for 12- and 16-Week Dosinghttps://modernod.com/news/aflibercept-8-mg-meets-primary-endpoints-in-two-global-pivotal-trials-for-dme-and-wet-amd-for-12-and-16-week-dosing/2481071/Regeneron Pharmaceuticals announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema (DME) and wet age-related macular degeneration (AMD). The PHOTON trial in DME and the PUL
- iOR Partners Appoints Health Care Industry Veteran James R. Williams as New President and CEOhttps://modernod.com/news/ior-partners-welcomes-health-care-industry-veteran-as-new-president-and-ceo/2481068/iOR Partners announced that James R. Williams has been appointed to serve as the company’s new President and CEO. Mr. Williams joined iOR as Chief Operating Officer (COO) earlier this year and served on the iOR Board of Directors for 2 years. Mr. Williams brings over 30